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The States "Race" with the Federal Government for
Stem Cell Research
Joanna K. Sax, Ph.D.
I. INTRODUCTION
Indicative of the political divide among American citizens, stem cell
research was one of the more hotly debated issues in the 2004 presidential
election, with strong support professed by Ron Reagan at the Democratic
National Convention.1 In the months leading up to the election, President
George W. Bush and Senator John Kerry presented different views
regarding the future of stem cell research in this country.2 Among Senator
Kerry's promises to America was a pledge to "lift the ban on federal
funding of research on stem cell lines created after August 2001." 
During the 2004 presidential race, President Bush expressed his views
about the future of stem cell research as well. In response to a question
posed about a particular scientific technique called somatic cell nuclear
transfer, he stated:
I believe all human cloning is wrong, and a total ban on human cloning is
necessary to ensure the protection of human life as the frontiers of
science expand. Anything short of a comprehensive ban would be
impossible to enforce and would permit human embryos to be created,
developed, and destroyed solely for research purposes. I strongly support
a comprehensive law against all human cloning.
The results of the November 2004 election mean that President Bush's
Ph.D. (2003) Cell and Molecular Biology, University of Pennsylvania; JD Candidate 2006,
University of Pennsylvania Law School. The author wishes to thank Gideon Parchomovsky,
Eric Feldman, Sean Griffith, Julie Lefebvre, Cobin Soelberg, John Fennel, Michael Liskow,
Kevin Goldman, Alex Sistla, Tim Kerr, Pia Sen, Amy Luria, and Yacov Silberman for
invaluable comments and criticisms.
1. Thomas Crampton, Ron Reagan Will Address Democratic Convention, N.Y. TIMES,
July 13, 2004, at A16. (discussing Ron Reagan's intent to speak "exclusively" about
loosening restrictions on stem cell research).
2. Bush and Kerry Offer Their Views on Science, SCIENCE, Oct. 1, 2004, at 46.
3. Id.
4. Id. at 47-48.
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positions on cloning and stem cell research will likely continue for the next
four years in federally-supported laboratories. However, some states have
recently taken steps to allow and even promote stem cell research.
5
States often serve as laboratories for national policy, with each state
experimenting with different approaches to a given issue. For example,
recognizing the medical, scientific, and economic benefits of stem cell
research, New Jersey and California passed legislation in 2004 to allow
stem cell research within their states.6 Most notably, Californians voted in
the November 2004 election for a $3 billion state referendum to fund stem
cell research over the next ten years.7 Stem cell research may also be
conducted with essentially no government oversight by using private
funds.
Other countries allow stem cell research under specific guidelines. For
example, while Great Britain promotes therapeutic cloning, it does not
allow- scientists to keep embryos for growth past fourteen days, thus
eliminating the potential for this technology to be used for human cloning.9
The British government created the UK Stem Cell Bank, to which scientists
must submit every new embryonic stem cell line to be evaluated and
maintained.' ° In addition, research in Great Britain may soon be further
regulated by the European Union, which has proposed guidelines to fund
stem cell research in countries where it is legal."
The goal of this paper is to analyze and explain the impact of state
5. See. e.g., N.J. REv. STAT. § 26:2Z-1 (2004) (permitting stem cell research in New
Jersey): C._ HEALTH AND SAFETY CODE § 125300 (2004) (permitting stem cell research in
California).
6. Id.
7. California Stem Cell Research and Cures Act, 2004 Cal. Legis. Serv. Prop. 71 (West).
(Voter "'Proposition 71" put a proposal to the vote of the public to use publicly-backed bonds
averaging S295 million annually over ten years to pay for stem cell research; the proposition
was passed in the 2004 election).
8. George Q. Daley, Missed Opportunities in Embryonic Stem Cell Research, 351 N.
ENG. J. MED. 627, 627 (Aug. 12, 2004) (noting that private funding is available but
unpredictable for such research).
9. Cynthia Donley Young, Comment, A Comparative Look at the U.S. and British
Approaches to Stem Cell Research, 65 ALB. L. REv. 831, 849 (2002) (citing the British
Human Fertilisation and Embryology Act, 1990, c. 37 (Eng.) 3(3)(a), 3(4), which addresses
the fourteen-day period); Elisabeth Rosenthal, Britain Embraces Stem Cell Research, N.Y.
TIMES. Aug. 24, 2004, at F6.
10. Rosenthal, supra note 9, at F6 ("Every new stem-cell line must be ceded to the
national bank, where it is evaluated and maintained, and may not be transferred elsewhere
without approval from a government steering committee.").
I1. Associated Press, World Briefing Europe: European Union Proposes Stem Cell
Rules, N.Y. TIMES, July 10, 2003, at A6 (noting that the European Union head office
proposed guidelines for financing research on embryonic stem cells, but excluded any
country where human embryonic stem cell research is forbidden).
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legislation and funding on the future of stem cell research. Without federal
law regulating stem cell research, funding by states and private
organizations may spur competition to attract and retain leading scientists
and industry in individual states. Alternatively, state-funded stem cell
research may incite the federal government to react either positively or
negatively to pre-empt state and private action. Traditionally, most support
for scientific research comes in the form of grants from the National
Institutes of Health (NIH).' Due to the practical ban on stem cell research
at the federal level, states have taken action to circumvent national
biomedical policy. Literally, the states are serving as laboratories for both
scientific research and policy decisions.
As a matter of public policy, the NIH should set uniform guidelines to
allow stem cell research, including provisions for the establishment of new
stem cell lines and funding for laboratories at the national level. There are
three main reasons for this policy. First, the federal infrastructure to fund
biomedical research is already established by the NIH. In order for the
states to form mini-institutes of health, much of the initial state revenue
would have to be allocated to fund the building of a state research institute
and to set up the necessary infrastructure.13 This is a waste of public money
when a functional national program already exists.
Second, competition among the states for using state money to fund
research is not the ideal method for strong scientific progress. Under this
model, with varying amounts of regulation between states, scientists in
State A may not be able to collaborate with scientists in State B because
State B prohibits stem cell research. A national policy, on the other hand,
would allow scientists in different states to work with each other as well as
with scientists around the world to promote stem cell research.
Third, the NIH has previously dealt with controversial research. In the
1970s, some people feared that recombinant DNA technology would lead to
biowarfare. 14  The NIH successfully established a committee to address
concerns by limiting the use of the technology to biomedical research. 5 A
12. Connie Bruck, Hollywood Science, NEW YORKER, Oct 18, 2004, at 64 (describing
the role of the NIH in the federal funding of scientific research); Nicholas Wade, Bush
Policy on Human Stem Cells Faces New Challenges, N.Y. TIMES, Mar. 4, 2004, at A18
(describing the "vast bulk of biomedical researchers" as supported by federal grants).
13. Jonathan Knight, Critics Slate Ethical Leeway in California Stem Cell Proposal, 431
NATURE 232 (Sept. 16, 2004) (stating that California's Proposition 71 will provide $3 billion
for embryonic stem cell research and infrastructure, including the distribution of grants by
the California Institute for Regenerative Medicine) [hereinafter Knight -Critics].
14. Bruck, supra note 12, at 67 ("In 1974, when [Berg] and his colleagues discovered
how to engineer recombinant DNA, it provoked fears of rampant super-microbes that might
be created by some errant laboratory.").
15. Id. (discussing how the research was able to progress); Erika Check, Biologists See
2006]
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similar committee could be established to oversee stem cell research and
address concerns by ensuring that scientists only perform therapeutic
research, not reproductive research. 16 The promise of stem cell research is
to help people afflicted with illnesses; 17 this should be a federal policy
because it affects citizens in every state and around the world.
Part II of this article explains the ethical divide surrounding the
technique of establishing embryonic stem cell lines. By describing the
scientific techniques used to establish stem cell lines and the potential to
help patients with many different types of diseases, I hope to communicate
that the promise of stem cell research is too great to be blocked by the
current federal policy. In Part III, I describe the federal policies regarding
stem cell research under Presidents Clinton and George W. Bush. To date,
the progress of stem cell research at the federal level lies in decisions made
by executive order. 18 Congress has considered several bills regarding stem
cell research, but the United States does not currently have federal law in
this area.' 9
In Part IV, I discuss initiatives, scientific and financial, undertaken by
private investors and states to support stem cell research. Part V considers
whether the state initiatives will create a state competition for researchers
and industry, using state competition under corporate law as a guide. I
argue that California may already be so far in the lead due to its
concentrated biomedical environment that, combined with the commitment
of $3 billion of state-funded stem cell research, 20 traditional state-
Consensus on Guidelines for Stem-Cell Research, 431 NATURE 885, 885 (Oct. 21, 2004)
(referring to the Recombinant DNA Advisory Committee, which is run by NIH).
16. Check, supra note 15, at 431 ("Other researchers proposed that scientists set up a
body similar to the Recombinant DNA Advisory Committee, which is run by the US
National Institutes of Health (NIH), to review questions on stem-cell research.").
17. See, e.g., NIH Director's Statement on Research Using Stem Cells, Before the
Senate Appropriations Subcommittee on Labor, Health and Human Services, Education and
Related Agencies (Jan. 26, 1999) (Statement of Harold Varmus, M.D., Dir., Nat'l Inst. of
Health), available at http://stemcells.nih.gov/policy/statements/statement.asp [hereinafter
NIH Director's Statement].
18. See, e.g., President George W. Bush, Remarks by the President on Stem Cell
Research (Aug. 9, 2001), available at http://www.whitehouse.gov/news/releases/2001/
08/20010809-2.html (last visited Oct. 20, 2005); Nat'l. Inst. of Health, NIH's Role in
Federal Policy: Stem Cell Research (2005), available at http://stemcells.nih.gov/policy/
NIHFedPolicy.asp (last visited Oct. 20, 2005) [hereinafter NIH's Role in Federal Policy.].
19. See, e.g. Jeffrey Brainard, After Heated Debate, U.S. House Votes Again to Ban
Cloning, 49 CHRON. HIGHER EDUC. A24, A24 (Mar. 14, 2003) (describing a stem cell bill
that was voted on in the House but does not have the votes to pass in the Senate); Denise
Grady, Debate Over Cloning in U.S. Remains Intense, N.Y. TIMES, Feb. 12, 2004, at B12
("[T]he United States has no federal laws regarding cloning, unlike Britain, which has
banned reproductive cloning while allowing research on therapeutic cloning.").
20. California Stem Cell Research and Cures Act, supra note 7.
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competition models do not apply. Nevertheless, other states may still
conduct stem cell research on a smaller scale, which calls for the
implementation of uniform federal guidelines for stem cell research.
California's initiative may invite the federal government to enact
legislation to preempt state law in such a way as to either support or further
hinder stem cell research; but if California is able to produce positive
results in the near future and the public begins to see the possible benefits, it
will be more difficult for the federal government to enact anti-stem cell
legislation. Therefore, the "race" is on between California and the federal
government to determine whether stem cell research will progress.
II. AN EXPLANATION OF STEM CELL RESEARCH
.4. Overview
Scientists who work with stem cells derive them from two main sources,
embryonic and adult cells.2 I During embryogenesis, cells are partitioned
into three layers,22 each subsequently giving rise to various tissues and
organs, transforming during development into skin, muscle, cartilage, etc.23
While these embryonic cells offer the greatest potential to treat many
human diseases, some adult tissues and organs retain stem cell dependence
for repair and so may also provide a viable option for treating human
ailments.
2 4
At the basic scientific level, stem cells offer great potential to treat many
types of diseases because they can undergo multiple divisions while
remaining undifferentiated in the laboratory.25 Upon stimulation, either
physiologically or experimentally, stem cells are induced to differentiate
into specific cell types, such as muscle. 6
Stem cells are classified along a spectrum defined by their ability to
transform into different cell types.27 These include:
totipotent (able to give rise to all embryonic and extra-embryonic cell
21. NAT'L. INST. OF HEALTH, STEM CELL INFORMATION: STEM CELL BASICS (2002),
http://stemcells.nih.gov/staticresources/info/basics/StemCellBasics.pdf. [hereinafter NIH
STEM CELL INFORMATION].
22. Amy J. Wagers & Irving L. Weissman, Plasticiy ofAdult Stem Cells, 116 CELL 639,
639 (Mar. 5, 2004) (describing the three germ layers: ectoderm, mesoderm, and endoderm).
23. Id.
24. Id.
25. NIH STEM CELL INFORMATION, supra note 21.
26. Id.
27. Wagers & Weissman, supra note 22, at 639.
20061
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types), pluripotent (able to give rise to all cell types of the embryo
proper), multipotent (able to give rise to a subset of cell lineages),
oligopotent (able to give rise to a more restricted subset of cell lineages
than multipotent stem cells), and unipotent (able to contribute only one
mature cell type).
28
Embryonic stem cells characteristically have more plasticity, meaning
they fall towards the totipotent and pluripotent end of the spectrum,
whereas adult stem cells may be more restrictive in their ability to
differentiate into multiple cell types .29
Most of the controversy surrounding stem cell research concerns the
process of obtaining embryonic stem cells. 30 Most notably, embryonic stem
cells can be obtained through in vitro fertilization procedures.31  Some
argue that it is morally and ethically wrong to create a human life only for
the purpose of destroying it.32 Proponents of stem cell research argue that
many fertilized eggs from fertility clinics will simply be destroyed anyway
and so would be useful for research.33 Opponents respond that the fertilized
egg has the potential for human life and cannot reconcile this view with the
purposeful destruction of that potential life in a scientific laboratory.
34
Proponents argue that human life has not yet begun in a petri dish.35 The
debate goes back and forth but basically comes down to a division between
those who believe that a fertilized egg should only give rise to a human
28. Id.
29. Id. at 639-40 (describing characteristic differences between embryonic stem-cells
and adult stem-cells).
30. Jason Scott Robert, Model Systems in Stem Cell Biology, 26 BIOESSAYS 1005, at
1005 (2004) ("Public debate over stem cell research has focused largely on scientific and
ethical questions about the sources of stem cells-embryonic, fetal, and 'adult' (or tissue
specific).").
31. Opinion, Disease Insights from Stem Cells, 422 NATURE 787, 787 (Apr. 24, 2003).
32. William Satire, Reagan's Next Victory, N.Y. TIMES, June 7, 2004, at A27
("Opponents say the harvesting of these cells destroys potential human life."). See also John
M. Broder & Andrew Pollack, Californians to Vote on Stem Cell Research Funds, N.Y.
TIMES, Sept. 20, 2004, at Al (describing that opponents to embryonic stem-cell research as
believing that "researchers must destroy human embryos, an act that is abhorrent to some
religious conservatives and opponents of abortion").
33. See Disease Insights from Stem Cells, supra note 31, at 787 ("[T]he existing cell
lines have all been derived from embryos left over from in vitro fertilization.") emphasis
added; Safire, supra note 32, at A27 ("[P]roponents say these are left over from in vitro
banks and already destined for destruction, donated by people to whom 'pro life' also means
saving the lives of suffering patients.").
34. Robert, supra note 30, at 1005 (describing ethical concerns that "isolating cells from
the inner mass destroys the embryo").
35. Lee L. Zwanziger, Biology, Ethics, and Public Policy: Deliberations at an Unstable
Intersection, 275B ANATOMICAL RECORD 185, 186 (2003) (describing that differing social
views contribute to the stem-cell ethical debate).
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being and those who believe that a discarded fertilized egg could be the key
to helping people affected with a variety of diseases.
The second ethical debate in stem cell research surrounds the technique
called somatic cell nuclear transfer.36 As will be described in more detail
below, this technique involves the transfer of one person's DNA into a
fertilized egg that has had its DNA removed. This is essentially the
technique used to create the cloned sheep "Dolly. 3 7 Opponents argue both
that it is wrong to destroy a potential human life and that this technique can
be used for human cloning.38 Proponents of stem cell research argue that
this technique can be used to study genetic diseases from affected patients
and that the egg will be destroyed within a few days of the DNA transfer. 3
To address the human cloning issue, one suggestion is to draw a line
between therapeutic and reproductive cloning by following the policy in
Great Britain, where eggs cannot be grown past fourteen days. 40  Taken
together, the main ethical divide is the technique for establishing an
embryonic stem cell line. This paper will set out the techniques and
potential benefits of stem cell research and hopefully elucidate that despite
the ethical divide, many lives can be improved and saved by supporting
stem cell research.
B. Why Study Stem Cells?
Three main properties of stem cells make them good candidates to treat
multiple types of disease: (1) they can divide many times and still remain as
undifferentiated cells, available to be later turned into a specific cell type
such as muscle; (2) they are not specialized to any specific cell-type
lineage; and (3) they can be induced to differentiate into a specific cell
type.41 While work with mouse (murine) stem cells has progressed over the
last twenty years, researchers have only been working with human stem
36. Disease Insights from Stem Cells, supra note 31, at 787 ("[T]here is opposition to
SCNT because it involves the production of human embryos for research.").
37. K.H.S. Campbell, et al., Sheep Cloned by Nuclear Transfer from a Cultured Cell
Line, 380 NATURE 64 (Mar. 7, 1996).
38. Laurie Goodstein & Denise Grady, Split on Clones of Embryos: Research vs.
Reproduction, N.Y. TIMES, Feb. 13, 2004, at A22 (quoting opponents of somatic cell nuclear
transfer on religious grounds as saying: '[w]e don't sacrifice one human life in order to
possible help another human life'; '[this research is] nothing short of cannibalism'; and
'[Koreans produced] human embryos for the explicit purpose of fatally mining them.').
39. Id. (noting that many, if not most, scientists support cloning to make embryonic stem
cells: "Those cells are prized for research because of their potential to become almost any
type of tissue, perhaps one day to be used to treat illnesses or injuries.").
40. Young, supra note 9, at 849.
41. NIH STEM CELL INFORMATION, supra note 21.
20061
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cells since 1998.42 To date, researchers are interested in understanding the
unique properties of stem cells and applying that knowledge to treat
disease.
One disease that receives particular attention in the press is Parkinson's
disease (PD), a neurodegenerative disease caused by the degeneration of a
particular type of neuron called dopamine-producing neurons.43 In mouse
models, scientists transplanted stem cells induced to differentiate into
dopamine-producing neurons, which successfully improved motor
function.4 The promise of applying a similar strategy in humans could lead
to a stem cell-based treatment for affected humans.
Type I diabetes research also stands to benefit from the potential of stem
cell research. The standard treatment for type I diabetes is to maintain a
particular level of blood glucose through insulin injections.45  However,
ideal blood glucose levels are difficult to achieve and patients suffer other
complications including kidney failure, stroke, amputation, and seizures.
4 6
In an attempt to find alternative approaches to treatment, researchers are
hopeful that islet cell transplantation may provide a treatment to restore
insulin-producing cells.47
Other major areas of research that will potentially benefit from stem cell
research include understanding the mechanisms of genetic diseases and
drug discovery.4" For example, scientists could create cell lines with the
same genetic lesions found in patients to study what goes wrong in the
diseased cellular process and these cells could then be used to screen for
molecules that stall or stop disease progression.49 Studies in murine stem
cells do not provide appropriate material to model human disease because
they often lack the capability to properly replicate human disease. Further,
murine stem cells often cannot be replicated in a genetic manner because
42 Id. See also Sylvia Kim, Embrvonic Stem Cell Research Controversy: Focus on the
Private Sector and International Sphere, 14 HASTINGS WoMEN'S L. J. 89, 89 (2003).
43. NIH STEM CELL INFORMATION, supra note 21.
44 Id.
45. Allen M. Spiegel & Gerald D. Fischbach, NIH Statement Before Senate
Appropriations Subcommittee, (Apr. 26, 2000), http://stemcells.nih.gov/policy/statements/
State.asp (explaining type I diabetes, current treatments, and potential complications).
46. Id.
47. Id. (stating that human pluripotent stem cells offer the best source of islet cells for
treating and curing type I diabetes).
4X Disease Insights from Stem Cells, supra note 31, at 787 (explaining that stem cell
research is important beyond "cell-replacement therapies," including "uncovering the
mechanisms of genetic diseases, and in generating sources of normal and impaired tissues
for use in drug discovery").
49 Id. (establishing an unlimited quantity of diseased tissue for use in experiments to
understand the molecular mechanism of disease and "'design high-throughput screens to
identify molecules that halt disease progression").
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some human ailments are too complex to be re-created in mouse models. 50
C. Embryonic Stem Cells
1. How Researchers Obtain Embryonic Stem Cells - A Basic
Understanding of Scientific Technique
Embryonic stem cells are obtained from eggs that have been fertilized in
vitro (i.e., in a test tube), not from eggs fertilized in a woman's body.51 The
fertilized egg is a totipotent cell that can give rise to an entire organism.
2
Approximately three to four days after in vitro fertilization, the cell mass
divides and forms a blastocyst containing multiple cells that are divided into
three concentric circles.5 3 The innermost layer contains a group of
approximately thirty pluripotent cells called the "'inner cell mass .- 54 This
layer is isolated to grow the stem cells in tissue culture.55
While each type of cell grown in a lab requires tweaking of the basic
tissue culture system, the following process applies to most cell types.56
Cells are grown on plastic petri dishes in a liquid, nutrient-enriched medium
containing sugar, salt, and other nutrients to feed the cells. 57 As cells grow
and divide, they fill up the petri dish and are then split into multiple dishes
in a process known as "passaging., 58 Once established, they can be frozen
50. Id. (noting that while it is feasible to generate ES-cell lines from mouse models of
human disease, the "underlying causes may be different from those of the human diseases
they are supposed to represent. And many human diseases are so complex or poorly
understood that mouse models do not exist for them.").
51. Id.
52. Spiegel & Fischbach, supra note 45 (explaining that ithen a sperm fertilizes an egg,
the product is a single totipotent stem cell that has the potential to form an entire organism).
See also Helen Pearson, Early Embryos Fuel Hopes for Shortcut to Stem Cell Creation, 432
NATURE 4 (Nov. 4, 2004). The article describes a study where researchers grew stem cells
out of a culture before it formed a blastocyst. Some researchers suggest that this new
technique may quell some ethical concerns because researchers are not destroying an entire
embryo. However, others suggest that opponents will remain steadfast in the belief that
"stem cell lines can only be created by destroying a human embryo."
53. NIH STEM CELL INFORMATION. supra note 21 (describing the culture conditions for
stem cells).
54. Id See also Robert, supra note 30, at 1005-06 ("After the third cell division, cells
begin to specialize, and an inner cell mass (1CM) forms within the blastocyst. Cells removed
from the 1CM are pluripotent, having less [compared to totipotent], but nonetheless
impressive, capacity for differentiation into various cell types (though pluripotent stem cells
cannot form placenta, some believe they can form the embryo).").
55. NIH Stem Cell Information, supra note 21 ("cell culture" is the technical term for
growing cells in a laboratory).
56. Id.
57. Id.
58. Id.
20061
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and shipped to other laboratories for experimentation.59
Embryonic stem cells require an extra step in the tissue culture process.
The petri dish used to plate the "inner cell mass" is first coated with mouse
feeder cells.60 The feeder cells provide a sticky surface to which the inner
cell mass adheres, and also release important nutrients and growth factors to
help the inner cell mass survive. 61 Scientists presently are devising ways to
use other means to plate the inner cell mass because they are worried about
the transfer of murine viruses or other molecules into the stem cells to be
used later in human patients.62
2. How to Differentiate Embryonic Stem Cells
Once the pluripotent stem cell line is established and characterized as
undifferentiated, cells can be used in experiments and can be stimulated to
differentiate.63 Scientists differentiate the cells into muscle, blood, or nerve
cells by changing the tissue culture conditions. 4 For example, specific
growth factors can be added to direct a cell to differentiate. 65 Alternatively,
scientists can genetically modify the cells by transfecting a specific gene
into the nucleus or DNA of the cell, which will cause the stem cell to
differentiate. These differentiated cells could then be used in human
patients to treat a variety of diseases.66
3. Another Way to Create Stem Cell Lines is by Somatic-Cell Nuclear
Transfer
To study mechanisms of human diseases and generate cell lines for drug
screening, scientists use somatic-cell nuclear transfer (SCNT) to create stem
cell lines from patients. 67  To create the "diseased" stem cell line, the
59. Id. ("established" means cells are growing well in tissue culture).
60. Id.
61. NIH Stem Cell Information, supra note 21. (describing the laboratory conditions for
embryonic stem cells).
62 Id.
63. Id. While establishing the stem cell line, scientists employ multiple tests to
determine whether they have established a stem cell line. These include, (1) growing the
cells for many months; (2) testing for specific cell surface that are only found on
undifferentiated cells (3) ensuring chromosomal stability; (4) determining the cells can
withstand a freeze/thaw so they can be frozen and then grown again; and (5) testing whether
the cells are pluripotent. Scientists do not have a consensus to experimentally test for many
of the previous conditions.
64. Id.
65. Id.
66. Id. (describing how to differentiate a stem cell).
67. See Disease Insights from Stem Cells, supra note 31, at 787 ("With current
technologies, generating new ES-cell lines from patients would require somatic-cell nuclear
[Vol. 1 5
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nucleus from a patient's cells is extracted and injected into an enucleated
egg. 68 The egg is then stimulated to divide in vitro and form a blastocyst.
69
After about five days of growth as described above, the inner cell mass is
extracted and cultured in vitro and then "induced to form the diseased
tissue."-70 The SCNT process has received opposition due to the perception
that it involves the production of human embryos for research, so it has
been lumped into the same general category of "cloning" and is subject to
regulation aimed mainly at preventing reproductive cloning.
71
D. Adult Stem Cells
Undifferentiated adult stem cells are found in "niches" in a variety of
72tissues and organs. Scientists believe the small number of adult stem cells
found in a particular tissue is in place to maintain or repair the tissue in case
of injury. 3 Originally, scientists found two kinds of stem cells in the bone
marrow; one gives rise to blood cells (hematopoietic stem cells), while the
other gives rise to "bone, cartilage, fat, and fibrous connective tissue.
More recently, scientists discovered small numbers of adult stem cells in
other tissues. 75  These discoveries have led scientists to try to grow adult
stem cells in tissue culture, characterize them, and attempt to differentiate
them so they can be used to treat disease.76
Scientists are presently studying a variety of issues to determine whether
transfer (SCNT).").
68. Id. (explaining that an enucleated egg is an egg without a nucleus.)
69. Id. at 787.
70. Id. (explaining the SCNT process to create diseased stem cells and tissues in vitro).
71. Id.
72. See NIH STEM CELL INFORMATION, supra note 21 ("An adult stem cell is an
undifferentiated cell found among differentiated cells in a tissue or organ, can renew itself,
and can differentiate to yield the major specialized cell types of then tissue or organ.");
Robert, supra note 30, at 1006 ("Some tissue-specific stem cells that are already
differentiated retain multipotent capacity to generate cells of a still more restricted class of
cell lineages; moreover, some stem cell biologists content that putatively tissue-specific stem
cells may 'dedifferentiate' and 'transdifferentiate' into other cell types.") (citations omitted);
Haifan Lin, The Stem Cell Niche Theory: Lessons From Flies, 3 NATURE REVIEWS GENETICS
931, 931 (Dec. 2002) ("[T]he stem cell niche refers specifically to the cells that are adjacent
to the stem cells to create an inductive microenvironment that maintains the stem cell fate
and prevents their differentiation.").
73. NIH STEM CELL INFORMATION, supra note 21 ("The primary role roles of adult stem
cells in a living organism are to maintain and repair the tissue on which they are found.").
74. Id.
75. Robert, supra note 30, at 1006 (noting characteristics that tissue-specific stem cells
have in common including: (1) relatively uncommon so therefore difficult to isolate, (2)
cycle slowly, (3) activity governed by microenvironment, (4) controversy surrounding self-
maintenance).
76. Wagers & Weissman, supra note 22, at 639-40 (describing adult stem-cell research).
2006]
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adult stem cells can be used to effectively treat disease. These issues
include: (1) determining which tissues contain stem cells; (2) examining the
source of adult stem cells; (3) differentiating in vivo and in vitro; and (4)
studying how adult stem cells kick into action once injury has occurred. 7
Recent studies suggest that adult stem cells may have more plasticity than
previously believed, meaning that stem cells isolated from one tissue may
be able to transform into cells of another tissue with the appropriate
stimulation.78 However, studies in this area are in the infant stage.79
E. A Comparison of Embryonic and Adult Stem Cells
Adult and embryonic stem cells each contain advantages and
disadvantages for research. One example is that adult stem cells may
already be further along in the differentiation process than embryonic stem
cells, so they only differentiate into specific lineages. On the other hand,
embryonic stem cells appear to have the plasticity to differentiate into all
cell types. 80 Low numbers of adult stem cells are found in each tissue and
the tissue culture conditions for these cells are not yet optimized. 8'
Alternatively, embryonic stem cells are easily expandable in tissue culture
conditions, which is important because large numbers of cells are required
82for experiments and therapies. A potential advantage of adult stem cells is
that the recipient could use his or her own cells, thus avoiding any potential
immunological rejection. However, it is unclear whether a patient would
reject donor embryonic stem cells.8 3
77. NIH STEM CELL INFORMATION, supra note 21 (describing a list of key questions
surrounding adult stem cells).
78. Wagers & Weissman, supra note 22, at 639 (explaining that the suggestion that adult
stem cells may trans-differentiate has in turn given rise to the concept of stem cell plasticity).
79. Id. at 644 ("Given the rarity with which events interpreted to represent
"transdifferentiation" have been detected in vivo, and the intense controversy surrounding
these findings, very stringent criteria should be required for the demonstration of a bona fide
trans-differentiation event."),
80. NIH STEM CELL INFORMATION. supra note 21 (describing the advantages and
disadvantages of adult and embryonic stem cells); Robert, supra note 30, at 1007 ("[I]n order
that hypotheses about the potential pluripotency of tissue-specific stem cells be neither
prematurely accepted nor prematurely rejected, comparative studies must be (and are being)
undertaken on all relevant types of stem cells. We do not want to conclude that Iadult' stem
cells as such are or are not pluripotent until we have shown this for every tissue-specific
stem cell system.").
81. NIH STEM CELL INFORMATION, supra note 21.
82 Id. (describing the advantages and disadvantages of adult and embryonic stem cells).
83. Id.
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F. Technical Bypass Options
In an attempt to bypass the embryo creation process, some researchers
have proposed alternative methods for nuclear transfer that may circumvent
the ethical dilemma surrounding experimental designs to obtain embryonic
stem cells.14  In November 2004, the President's Council for Bioethics
heard two proposals that might bypass the "destruction of an embryo"
ethical dilemma. 85  The first proposal would define an embryo as
"nonviable before any cells are taken from it."' 86 The second alternative
contained a proposal whereby the DNA is "jinxed" before being transferred
into an egg.87  In this second method, DNA missing key developmental
genes is used for the transfer into an enucleated egg using the SCNT
technique.88 This would allow the cells to divide and form embryonic stem
cells, but it would not allow an embryo to be formed and later
"destroyed., 89 To date, this technique is purely theoretical and it will take
experimental progress to determine efficiency and feasibility. 90 Other
scientific proposals to sidestep the "destroyed embryo" ethical debate
include: parthenogenesis (tricking an unfertilized egg into dividing by
mimicking the effect of a sperm), use of defunct (i.e., nonviable) embryos
created for in vitro fertilization, isolating a single cell from a pre-blastocyst
or a blastocyst without destroying the entire blastocyst, and changing
mature cells into pluripotent stem cells. 9'
84. Constance Holden & Gretchen Vogel, A Technical Fx for an Ethical Bind?, 306
SCIENCE 2174, 2174 (Dec. 24, 2004) (discussing that new ways to create stem cell lines
"would enable scientists to sidestep the ethical debate that has polarized the United States
and triggered governments around the world to become involved to an unprecedented degree
in regulating research.").
85. Id.
86. Id.
87. Id.
88. Id.
89. Holden & Gretchen, supra note 84 (stating that knocking out a key developmental
gene before transferring the nucleus of a donor cell into an enucleated egg cell would allow
for creation of a reprogrammed cell capable of forming ES cells but lacking the signals
needed to form an organized embryo. "No embryo created. . . no embryo destroyed.").
90. Id. at2175.
91. Id. at 2175-76 (discussing the experimental status and future prospects for a variety
of alternative experimental procedures to obtain stem cells).
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III. AN OVERVIEW OF RECENT NATIONAL AND STATE POLICY
OF STEM CELL RESEARCH
The NIH contributes to the advancement of science through various
programs, including those that train scientists and issue research grants.
92
Increased funding in new avenues of promising research is important to
help those affected with degenerative diseases and to continue the NIH's
record of improving human health. 93  In 1998, at President Clinton's
request, the National Bioethics Advisory Commission reviewed medical
and ethical issues related to human stem cell research and with the support
of the Department of Health and Human Services, recommended that
responsible funding of embryonic stem cell research be permitted.94 In a
statement made to the Senate Appropriations Subcommittee on Labor,
Health and Human Services, Education and Related Agencies, Harold
Varmus, Director of the NIH under President Clinton, explained the
advantages of federally funded research:
There are a number of advantages to using public funding for research.
Perhaps the most important reason is the fact that Federal involvement
creates a more open research environment - with better exchange of ideas
and data among scientists - more public engagement and more oversight.
In addition, Federal support increases the fiscal resources and expands
the pool of talented investigators - particularly in academia - both of
which accelerate the tempo of scientific discovery.
95
In this address, Varmus explained three potential applications of stem
cell research. First, scientific understanding of the normal function of cells
and tissues provides insight into what is different and wrong in cell types
that deviate from the healthy path.96 An example of this type of research is
studies done by cancer researchers who compare normal and tumor cells to
learn what changes transform a healthy cell into a cancer cell.97 Second,
stem cells could be used in pharmacological screenings to study the
92. See Bush and Kern, Offer Their Views on Science, supra note 2, at 51 (noting that in
2004, the NIH trained 1500 more scientists per year and issued 10,000 more research grants
than it did in 1998).
93. Id. See also S.B. 1909, 2004 Leg., 210th Sess. (N.J. 2004) (permitting stem cell
research in New Jersey).
94. Kim, supra note 42, at 99 (describing the history of the federal policy on stem cell
research).
95. NIH Director's Statement, supra note 17.
96. Id. ("Studying normal cell and tissue development will provide an understanding of
abnormal growth and development which, in turn, could lead to the discovery of new ways
to prevent and treat birth defects and even cancer.").
97. Id
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potentially toxic effects of newly developed drugs. 9' Third, stem cells
provide the potential to direct the specialization of these undifferentiated
cells to be used for transplants." Two particularly exciting areas falling
within this last use include heart disease and type I diabetes. 100
Soon after the NIH published guidelines for conducting research with
stem cells in the Federal Registrar, the scheduled review of pending grant
applications on April 25, 2001, was postponed while President George W.
Bush's administration reviewed this area of research.'0 ' Then, in August of
2001, President Bush banned through executive order federal funding of
stem cell research for all practical purposes. 10 2 President Bush based his
decision on his personal "'belief in the fundamental value and sanctity of
human life."'10 3 Following President Bush's statement, the NIH announced
that stem cell research would be funded only if the following criteria were
met:
The derivation process (which begins with the destruction of the embryo)
was initiated prior to 9:00 EDT on August 9, 2001. The stem cells must
have been derived from an embryo that was created for reproductive
purposes and was no longer needed. Informed consent must have been
obtained for the donation of the embryo and that donation must not have
involved financial inducements. 04
This policy banned federal funding for: "(1) the derivation or use of stem
cell lines derived from newly destroyed embryos; (2) the creation of any
human embryos for research purposes; or (3) the cloning of human embryos
for any purpose."' 05  Technically, the Bush administration is the first to
98. Id. ("Use of human pluripotent stem cells could allow researchers to study the
beneficial and toxic effects of candidate drugs in many different cell types and potentially
reduce the numbers of animal studies and human clinical trials required for drug
development.").
99. Id. (stating that the third and most obvious potential application of these human
pluripotent stem cells is specialization of the cells into tissues that could be transplanted into
patients for the purpose of repairing injury and pathological processes).
100. Id. (citing heart disease and type I diabetes as examples of the potential of stem cell
research in treating disease).
101. Nat'l. Inst. of Health, Archived Stem Cell Research and Legislation,
http://stemcells.nih.gov/policy/legislation/archive.asp (last visited Sept. 22, 2005)
[hereinafter Archived Stem Cell Research and Legislation].
102. President George W. Bush, Remarks by the President on Stem Cell Research (Aug.
9, 2001), available at http://whitehouse.gov/news/releases/2001/08/print/20010809-2.html.
103. Office of the Press Secretary, Fact Sheet: Embryonic Stem Cell Research (Aug. 9,
2001), available at http://www.whitehouse.gov/news/releases/2001/08/print/20010809-
lhtml [hereinafter Fact Sheet]. See also President George W. Bush, supra note 102 ("My
position on these issues is shaped by deeply held beliefs.").
104. NIH's Role in Federal Policy: Stem Cell Research, supra note 18.
105. Fact Sheet, supra note 103.
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fund human embryonic stem cell research.10 6  To the non-scientifically
trained American, this policy appeared to be a good compromise in the
ethical debate surrounding stem cell research. However, to the trained
scientist, this policy effectively banned stem cell research because it
remains to be proven if any of the approximately sixty cell lines established
prior to August 9, 2001, could actually be used to advance scientific
research. 107
In addition to his own moral beliefs, President Bush partly relied on
advice given by the President's Council on Bioethics (PCB), a federal
advisory committee headed by Leon Kass. Selected by the President and
heads of departments, federal advisory committees are meant to provide
expert and objective advice on various issues.108 However, many members
of the scientific community feel that President Bush does not appoint or
even dismisses committee members who do not share his personal
beliefs. 0 9 A recent report by the Union of Concerned Scientists noted:
[T]here is a well-established pattern of suppression and distortions of
scientific findings by high-ranking Bush administration political
appointees across numerous federal agencies ... [and] there is strong
documentation of wide-ranging effort to manipulate the government's
scientific advisory system to prevent the appearance of advice that might
run counter to the administration's political agenda."l0
However, the Bush administration vehemently objects, asserting that no
106. Bush and Kern
, 
Offer Their Views on Science, supra note 2, at 47 ("My
administration is the first to allow federal funding for human embryonic stem cell
research."); Office of the Dir., Nat'l Inst. of Health, NIH Guide: Notice of Criteria for
Federal Funding of Research on Existing Human Embronic Stem cells and Establishment
of NIH Embryonic Stem Cell Registry, available at http://grants.nih.gov/grants/guide/notice-
files/NOT-OD-02-005.html (last visited Oct. 30, 2005) ("On August 9, 2001... the President
announced his decision to allow Federal funds to be used for research on existing human
embryonic stem cell lines.").
107. Elias Zerhouni, Stem Cell Programs, 300 SCIENCE 911 (May 9, 2003) ("By early
winter of 2001, 71 independent human embryonic stem cell derivations were identified on
the NIH Human Embryonic Stem Cell Registry as eligible for research supported by federal
funds.").
108. Robert Steinbrook , Science, Politics, and Federal Advisory Committees, 350 N.
ENG. J. MED. 1454, 1454 (Apr. 1, 2004) ("Federal advisory committees are meant to provide
independent, expert, and objective advice on policy, the funding of research, and other
issues. Although their advice may be followed, or ignored, they do not make decisions.");
Federal Advisory Committee Act, Pub. L. No. 92-463 (Oct. 6, 1972).
109. Steinbrook, supra note 108, at 1454 (noting that "candidates have reportedly been
asked to state their views on specific topics, such as abortion, stem cell research, and human
cloning.").
110. Id. at 1456 (quoting Union of Concerned Scientists, SCIENTIFIC INTEGRITY IN
POLICYMAKING: AN INVESTIGATION INTO THE BUSH ADMINISTRATION'S MISUSE OF SCIENCE 2
(Feb. 2004), available at http://www.ucsusa.org).
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litmus test is used to appoint committee members.'''
President Bush recently came under criticism when he did not reappoint
two stem cell research proponents, suggesting that dissent was not
appreciated on the Council.'"2 One scientist, Elizabeth Blackburn, charged
the administration with replacing pro-stem cell members with persons
whose beliefs lie closely to those of Leon Kass."' Furthermore, Blackburn
worries that strong data regarding the promise of stem cell research is being
purposefully left out of the Council's report, suggesting bias against
funding." 4 Practically speaking, however, it may be almost impossible to
separate advisory committees from politics." 5  To address some of the
recent criticisms, two reports from the General Accounting Office and the
National Academies will examine issues including federal appointments,
adequacy of the procedure to ensure scientifically sound advice, and quality
of the peer review system.'"
In a hearing before the 108th Congress, Elias Zerhouni, Director of the
NIH under President Bush, reported on the progress of stem cell research.'"
In this address, Zerhouni reported that seventy-eight stem cell lines are
"fully eligible for federal funding" and that eleven stem cells lines are
"widely available for all researchers." ' 8 While a limited number of stem
cell lines are available for federally funded research, even proponents of the
111. Id. at 1455 (noting that the Bush administration defends its actions); Aaron Zitner,
Advisors Put Under .4 Microscope, L.A. TIMES, Dec. 23, 2003, at Al.
112. Steinbrook, supra note 108, at 1454. See also Elizabeth Blackburn, Bioethics and
the Political Distortion of Biomedical Science, 350 N. E.G. J. MED. 1378, 1379 (Apr. 1,
2004) (discussing her personal experience of being asked to leave the President's Council on
Bioethics).
113. Blackburn, supra note 112. at 1379 ("The published views of the three new
members differ sharply from mine and May's and are much closer to those espoused by
Kass. Furthermore, not one of the newly appointed members is a biomedical scientist.").
114. Id. at 1380 ("[W]ork with animals increasingly suggests that research may result in
therapies for diabetes, Parkinson's disease, and spinal injuries among other conditions. Yet
the best possible scientific information was not incorporated and communicated clearly in
the council's report, suggesting that the presentation was biased.").
115. Steinbrook, supra note 108, at 1458 (quoting G. Calvin Mackenzie as stating,
"[i]nsulating appointments to advisory committees from politics is just about an
impossibility.").
116. Id. at 1459 (noting that as a result of the controversies surrounding federal advisory
committees, two potentially influential reports are forthcoming).
117. Stem Cell Research, Hearing Before Senate Appropriations Subcommittee on
Labor, Health and Human Services, and Education (Session 1), 108th Cong. (Statement of
Elias A. Zerhouni) (May 22, 2003), available at http://olpa.od.nih.gov/hearings/108/
sessiun 1/testimonies/stemcell.asp (last visited Nov. 2, 2005)(commenting on the progress of
stem cell research under the Bush administration).
118. Id. See also Paul McHugh, Zygote and "Clonote "- The Ethical Use of Embryonic
Stem Cells, 351 N. ENG. J. MED. 209, 209 (July 15, 2004) (noting that the NIH has made "15
to 20 human stem cell lines available for federally supported research.").
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current policy acknowledge that some technical barriers make the current
fontim for research even more challenging. 19 The current stem cells lines
"may be difficult to grow and differentiate"' 120 and the genetic origin and
culture conditions of the established cell lines may affect scientific
progress.121
Members of the scientific community are extremely critical of the current
stem cell policy. One scientist argues that the practical ban on stem cell
research in this country will undermine the ability of our scientists to
compete internationally. 22  Should stem cell research later become
unrestricted, we will then lack a work force prepared to work on potential
breakthrough discoveries in other countries. 1 Others argue that religious
and political tests should not be used in determining scientific policy. 24
Scientists also believe that current stem cell lines most likely have limited
potential for use in clinical therapy due to mouse contamination. 1
25
Finally, we currently lack the ability to create cell lines to model
diseases. 126 In a survey taken at a stem cell research conference, a majority
of researchers opined that there are not enough stem cell lines for research
and that the current federal policy hinders research. 27 Indeed, research in
119. Stem Cell Research, Hearing Before Senate Appropriations Subcommittee on
Labor, Health and Human Services, and Education (Session 1), 108th Cong. (Statement of
Ronald McKay) (May 22, 2003), available at http://olpa.od.nih.gov/hearings/108/sessionl/
testimonies/stemcell.asp (last visited Nov. 2, 2005)
120. Id.
121. Id. (noting that many early stem cell lines were established by co-culturing the cells
with mouse feeder cells).
122. Jeffrey M. Drazen, Embrvonic Stem cell Research -The Case for Federal Funding,
351 N. ENG. J. MED. 1789, 1789 ("If we continue to prevent federal funds from being used
to support this research in the United States, the ability of our biomedical scientists to
compete with other research teams throughout the world will be undermined.").
123. Id. ("[W]ithout the needed laboratory know-how, as a result of our current federal
policy of permitting research with only a limited number of preexisting embryonic stem cell
lines, these experiments [referring to a stem cell related breakthrough in another country]
could take years to complete, and replication would be likely to happen outside the United
States.").
124. David Baltimore, Science and the Bush Administration, 305 SCIENCE 1873, 1873
(Sept. 24, 2004) ("In various ways, the scientific community in the United States-and in
other nations as well-has expressed concerns about the way in which decisions about
scientific issues have been subjected to political tests by the Bush administration.").
125. Daley, supra note 8, at 627 ("All were cultured in contact with mouse cells and
bovine serum, which renders them inferior to newer lines, derived under pristine conditions,
for potential therapeutic applications.")
126. Id. ("More important questions can be addressed only by means of the lines
modeling specific diseases, and therapies may best be pursued with lines genetically
matched to specific patients through somatic-cell nuclear transfer.").
127. Amanda L. Drake et al., Letter to the Editor. Researcher Opinions on Human
Embrvonic Stem Cell Issues, 122 J. INVESTIG. DERMATOLOGY 855, 855 (2004) (discussing
the results of a survey taken to determine scientific opinions about the current state of stem
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foreign countries has already addressed some of the concerns put forward
by American scientists, including how to culture new stem cells lines not
contaminated with mouse feeder cells. 28  As previously noted, Great
Britain recently implemented policies to encourage growth and progress in
stem cell research, including opening a stem cell bank 29 and issuing
licenses to use cloning techniques, namely SCNT, to establish stem cell
lines. 130  Some argue the "scientific epicenter" for stem cell research is
shifting overseas, where countries like Great Britain support the research
under "strictly monitored conditions.,"3'
Several bills have been proposed by members of Congress, voted on in
the House, or referred to committees.13  On February 27, 2003, the House
voted in favor of a bill that would prohibit both therapeutic and
reproductive cloning and include a criminal penalty for violation. 133 About
the same time, a number of senators introduced a bill that allowed
therapeutic cloning, but banned reproductive cloning."' While other bills
remain either on the floor or in committee, Congress has yet to make a
definitive statement on the future of stem cell research.
IV. PRIVATE INVESTORS AND INDIVIDUAL STATES ARE
TAKING THE LEAD IN STEM CELL RESEARCH
Private organizations and individual states are implementing programs
and funding to advance research. Researchers at Harvard University,
cell research).
128. Daley, supra note 8, at 627 (stating scientists in Singapore have cultured
uncontaminated new lines that are therefore preferable for use in human patients).
129. Laura Nelson, Britain Opens First Repository to Speed Work On Stem Cells, 429
NATURE 333, 333 (May 27, 2004); Rosenthal, supra note 9, at F6.
130. Rosenthal, supra note 9, at F6; Heather Timmons, Britain Grants License to Make
Human Embryos for Stem Cells, N.Y. TIMES, Aug. 12, 2004 at A4 (noting that the country's
first license to use cloning techniques to generate a human embryo to produce stem cells was
issued).
131. Rosenthal, supra note 9, at F6; Alison Abbot, Czech Stem Cell Work Heightens
Calls for EU Ruling, 424 NATURE 602, 602 (Aug. 7, 2003) (noting that scientists in the
Czech Republic also performing stem cell research); David Cyranoski, Japanese Team
Makes Stem Cells, 423 NATURE 577, 577 (June 5, 2003) ("Japan has joined the club of
countries that have produced their own human embryonic stem cell lines."); Associated
Press, supra note 11; World Briefing Europe: European Union Proposes Stem Cell Rules,
N.Y. TIMES, July 10, 2003, at A6 (reporting that the European Union is also proposing
guidelines to fund stem cell research in European Union countries where it is legal).
132. Archived Stem Cell Research and Legislation, supra note 101.
133. Id. See also Human Cloning Prohibition Act of 2003, H.R. 534, 108th Cong.
(2003).
134. Human Cloning Ban and Stem Cell Research Protection Act of 2003, S. 303, 108th
Cong. (2003); Archived Stem Cell Research and Legislation, supra note 101.
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funded by private money, are opening a stem cell research center.135 In
2004 both New Jersey and California passed legislation allowing and/or
funding stem cell research. 36  Initiatives such as these show that some
states so strongly believe in stem cell research, either for medical, political,
or economic reasons, that they are willing to support research that the
federal government is not willing to presently fund.
A. Privatization of Stem Cell Research
Recently, Harvard University announced its plan to open the Harvard
Stem Cell Institute. 37 In consideration of the ethical debate, the Harvard
Stem Cell Research Committee will review research proposals for the
Institute. 138 The Institute proposes to contribute to research that may be
done at laboratories outside of Harvard, establish core facilities to work
with stem cells, and bring scientists together through seminars and
symposiums. 139 Proponents of the private institute believe that scientific
progress in stem cell research and its application to disease will challenge
the ethical opposition in favor of increased funding to help those affected
with illnesses. 140
Earlier in 2004, Harvard researchers made seventeen embryonic stem
cell lines available to other laboratories.' 4' While some acknowledge that
the stem cell lines made available by the NIH may be enough to get the
field started, private funding will be needed to produce additional cell lines
and fund further research. 142 Moreover, researchers working with the newly
available cell lines from Harvard will require private funds to perform the
research due to current federal prohibitions.
1 43
135. Alvin Powell, From the Laboratory to the Patient, HARv. UNIV. GAZETTE, Apr. 22,
2004, http://www.news.harvard.edu/gazette/2004/04.22/99-StemOver.html.
136. CAL. HEALTH AND SAFETY CODE § 125300 (West 2004); N.J. STAT. ANN. § 26:2Z-2
(West 2004).
137. Powell, supra note 135.
138. Id. (discussing committee created to review research proposals for non-federally
funded projects).
139. Id (describing the goals of the Institute).
140. Harvard Plans Center to Grow Stem Cells, N.Y. TIMES, Mar. 1, 2004, at A18
(opining that with every success, Americans will not stand for scientists unable to work on
diseases).
141. Editorial, The Privatization of Stem Cells, N.Y. TIMES, Mar. 9, 2004, at A24
(stating that private and state funding may be needed to expand research as new embryonic
stem cell lines are made available).
142. Id. (noting that additional stem cell lines will be required for research to move
forward).
143. Id. (noting that research on new stem cell lines will require private financing).
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B. State Legislatures are Passing Bills to Allow and Fund Stem Cell
Research
While some states such as Missouri and Kansas have specifically banned
embryonic stem cell research, 44 other states including New Jersey and
California passed legislation allowing stem cell research.145 The motivation
behind passing bills allowing stem cell research may be, in part, the hope of
contributing to state economic growth.
146
1. New Jersey Passes Pro-Stem Cell Research Legislation
New Jersey recently passed stem cell research legislation and stated:
Open scientific inquiry and publicly funded research will be essential to
realizing the promise of stem cell research and maintaining the State's
leadership in biomedicine and biotechnology. Publicly funded stem cell
research, conducted under established standards of open scientific
exchange, peer review and public oversight, offers the most efficient and
responsible means of fulfilling the promise of stem cells to provide
regenerative medical therapies.
The New Jersey bill allows all types of stem cell research (including
adult, embryonic, and SCNT), sets up an institutional review board to
review stem cell research, and states that information will be presented to
infertility patients about their options to donate unused embryos to
research. 48 While it was legal to perform stem cell research with private
money prior to the passing of the New Jersey bill, the new bill "amounts to
a proclamation in support of the science.' 49
Economic considerations of the state's biotechnology industry also
played a role in the decision to pass stem cell legislation. The New Jersey
bill states: "The biomedical industry is a critical and growing component of
New Jersey's economy, and would be significantly diminished by
144. Paul Smaglik, Stem-Cell State Lines, 429 NATURE 905, 905 (June 24, 2004)
(explaining that Missouri and Kansas have anti-stem cell research policies).
145. CAL. HEALTH AND SAFETY CODE § 125300 (2004); N.J. STAT. ANN. § 26:2Z-2
(West 2004).
146. Smaglik, supra note 144, at 905 (explaining that "university officials and biotech
leaders" in both Missouri and Kansas hoped to pass economic development packages to
recruit researchers, but the bills were either rejected (Missouri) or limited (Kansas) by
banning embryonic stem cell research).
147. N.J. REv. STAT. § 26:2Z-lf(2004).
148. N.J. REV. STAT. § 26:2Z-2 (2004), See also Jeremy Pearce, Entering a Brave New
World, Warily, N.Y. TIMES, Jan. 18, 2004, at 14NJ I (explaining particular provisions of the
bill).
149. Pearce, supra note 148, at 14NJ 1.
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limitations imposed on stem cell research."' 50  In May 2004, Governor
James McGreevey signed legislation establishing a "state-supported stem
cell research facility"'151 and about 200 researchers attending the forum said,
"they hoped the institute would help New Jersey retain its status as a center
for pharmaceutical and biotech research."'' 2  In addition, state officials
commented on the contribution of scientific research to the state economy,
noting that, "120 biotech research businesses in New Jersey employed
8,000 people and created $1 billion in revenue for the state economy." 53
Supporters of the bill hope that the pro-stem cell legislation will attract
scientists from around the world,'5 4 as well as biotech and pharmaceutical
industry to the state.' 55 For instance, after California passed pro-stem cell
legislation in 2002, that state experienced an influx of researchers and
received private funding for a Stanford University stem cell research
center. 56 New Jersey hopes for a similar investment trend.
2. California Passes a Referendum and $3 Billion in Funding for Stem Cell
Research
California initially passed a bill allowing therapeutic stem cell research
in 2002, but that bill was unfunded.'5 7 Then, in 2004, Californians voted on
and passed a stem cell referendum allowing embryonic stem cell research,
adult stem cell research, and SCNT. 58 That measure also required that all
150. N.J. REV. STAT. § 26:2Z-le (2004).
151. John M. Broder & Andrew Pollack, Californians to Vote on Stem Cell Research
Funds, N.Y. TIMES, Sept. 20, 2004, at Al (reporting that Governor McGreevey signed the
legislation establishing a state-supported stem cell research facility).
152. David Kochieniewski, McGreevey Signs Bill Creating Stem Cell Research Center,
N.Y. TIMES, May 14, 2004, at B5; See also Laura Mansnerus, New Jersey Forges Ahead on
Stem Cells, N.Y. TIMES, Feb. 21, 2004, at BI (noting that the budget will provide $6.5
million for a research institute to be run by Rutgers University and the University of
Medicine and Dentistry of New Jersey).
153. Kochieniewski, supra note 152, at B5.
154. Mansnerus, supra note 152, at B1 (noting that Dr. Wise Young and other
researchers hoped to recruit about a dozen of "the best stem cell scientists in the world,"
which would cost about $25 million).
155. Laura Mansnerus, Stem Cell Law Welcomed by Researchers, N.Y. TIMES, Jan. 6,
2004, at B6 (.'If you were a biotech, would you invest millions of dollars and jobs in a state
that might outlaw what you're doing?"').
156. Id.
157. Mansnerus, supra note 152, at B1.
158. CAL. HEALTH & SAFETY CODE § 125300(a) (West 2004) ("That research involving
the derivation and use of human embryonic stem cells, human embryonic germ cells, and
human adult stem cells from any source, including somatic cell nuclear transplantation, shall
be permitted and that full consideration of the ethical and medical implications of this
research be given.").
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research be reviewed by "an approved institutional review board."'15 ') The
California bill acknowledges the "promise for developing new medical
therapies" and notes the effect on the California economy:
California's biomedical industry is a critical component of the state's
economy that provides employment in over 2,500 companies to over
225,000 Californians, pays S12.8 billion in wages and salaries, invests
more than S2.1 billion in research, and reports nearly $7.8 billion in
worldwide revenue, and would be significantly diminished by limitations
imposed on stem cell research.160
Unlike New Jersey, however, California placed a $3 billion funding
initiative on the November 2004 ballot to allow citizens to vote on
providing public funding of stem cell research. '61
Proposition 71, backed by Governor Arnold Schwarzenegger, was a
ballot initiative providing S3 billion for stem cell research over the next ten
years. 162  Robert Klein, a real-estate developer and major author and
promoter of Proposition 71, stated that the $3 billion price tag was needed
to mimic a national funding program. 63  Klein argued that California,
though already in financial trouble, could afford the initiative by putting the
debt obligations off to the future by using bond proceeds to pay off the
interest and partly relying on economic growth from the promise of stem
cell research to help pay off the rest.164 Proposition 71 also establishes the
California Institute for Regenerative Medicine, which will award research
funding to grant applicants. 16 -  The core clauses of the initiative were
inserted into the California constitution and so will require a 70%
legislative majority to make any changes, effectively eliminating legislative
159. CAL. HEALTH & SAFETY CODE § 125300(b) (West 2004).
160. CAL. HEALTH & SAFETY CODE § 125300 (West 2004).
161. Broder & Pollack, supra note 32, at Al.
162. Jonathan Knight, Schwvarzenegger Endorses Stem Cell Push, 431 NATURE 888, 888
(Oct. 21 2004) (reporting that after months of silence, Schwarzenegger backed the state's
ballot initiative to fund embryonic stem cell research) [hereinafter Knight -
Schwarzenegger]. Schwarzenegger Backs Stem Cell Research, N.Y. TIMES, Oct. 19, 2004, at
A23, (reporting on Schwarzenegger's endorsement of the $3 billion bond measure to finance
human embryonic stem cell research, although it put him at odds with the state Republican
party).
163. Bruck, supra note 12, at 70 (quoting Klein's argument that "a billion would not
sufficiently support what he has devised: a ten-to-thirteen year program moving from basic
applied research to clinical trials to therapy development," and that it will take $3 Billion to
run a substitute national program).
164. Id. (explaining how Klein proposed to fund Proposition 71).
165. Id. (explaining that the California Institute for Regenerative Medicine is to award
the research grants, and will be governed by a twenty-nine-member board, consisting of
representatives of universities, medical-research institutions, and patient-advocacy groups).
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oversight. 166
Interestingly, opponents of Proposition 71 included both pro-stem cell
research groups and anti-stem cell organizations, albeit for different
reasons. 167 The more liberal camps that traditionally support progressive
views regarding abortion rights argue that Proposition 71 "lacks adequate
ethical safeguards against financial conflicts of interest.' 68 They argue the
lack of legislative oversight will allow the Research Institute to "make its
own rules about conflicts of interest and informed consent.' 69 Anti-stem
cell research persons and organizations posit the same ethical dilemmas
described at the national level, including ethical objections to the
destruction of blastocysts and the potential for reproductive cloning.
70
Besides ethical considerations, others argue that California is already so far
in debt that this initiative is fiscally irresponsible.' 7 '
Proponents of Proposition 71 argue the "initiative will more than pay for
itself." 72  Spending on buildings and research staff will generate tax
revenue and, when combined with stimulation of the state's biotechnology
industry and better therapies that economize medical costs, the initiative
costs will be covered. 73 Proponents also contend that the proposal for the
California Institute for Regenerative Medicine will provide the "highest
possible level of accountability and will serve as a model of how science
can be funded at the state level.' 74
Irv Weissman, one of the strongest proponents of Proposition 71,
explained in a recent interview that passage of the proposition will enable
California to attract some of the best scientists in the United States.' 75
166. Id. (noting that the initiative's core clauses will be incorporated as an amendment
to the California Constitution, thereby creating a constitutional right to conduct stem cell
research in California); Jonathan Knight, War of Words Escalates in Run-Up to California's
Vote on Stem Cells, 430 NATURE 125, 125 (July 8, 2004) (explaining that Proposition 71 will
not only establish a California Institute for Regenerative Medicine to distribute grant money
through a review process, but also by amending the constitution and requiring a 70%
legislative majority to make changes to the proposition, the initiative seeks to make
California a haven for this research) [hereinafter Knight - War].
167. Knight - Schwarzenegger, supra note 162, at 888.
168, Id.
169. Knight- Critics, supra note 13, at 232.
170. Id. at 23 2.
171. Knight - Schwarzenegger, supra note 162, at 888.
172. Id.
173. Id ("Spending on buildings and research staff alone will generate enough tax
rcvenue to ... cover the first five years' interest on the bond. [T]he bond should stimulate
the state's biotechnology industry and give better therapies that will save tens of millions of
dollars in medical costs each year.").
174 Knight - Critics, supra note 13, at 232.
175. Bruck, supra note 12, at 78.
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Weisman predicts that scientists will relocate to California, leaving other
states at a competitive disadvantage, "and probably only then will the state
legislatures and the federal government wake up to realize that California is
stealing, for a song, these scientists and building a whole future."
17 6
Another strong supporter of Proposition 71, former NIH director Harold
Varmus, stated, "I think that the symbolic value of having some state doing
[stem cell research] with public money, to embarrass the federal
government and try to encourage it to get back in the game, would be very,
very important."' 1 7  But Varmus expressed concerns that state-by-state
funding initiatives are not an adequate substitute for NIH policies and
funding and stated that he would like the federal government to change the
current policy. 178 The only way President Bush could undermine the future
funding of stem cell research would be to pass federal law outlawing
therapeutic cloning. A bill to this effect has already failed twice in the
Senate, thus the chances of a federal ban passing look slim.
7 9
The promise of funded stem cell research in California may indeed lead
prominent researchers in other parts of the country to move to there, thus
weakening the potential for embryonic stem cell research in other states.8 °
Other states may therefore miss out on a huge economic opportunity if their
researchers leave before the state legislatures pass pro-stem cell policy. To
this end, some hypothesize that other states may follow California's lead.' 8'
Indeed, the governors of both Wisconsin and New Jersey have since
proposed spending millions of dollars on their state's biotech and
biomedical research.'
8 2
Even though the federal government is not funding laboratories that want
to establish new stem cell lines, public money is still being used to promote
176. Id.
177. Id. at 80.
178. Id. (stating that there really is no substitute for the NIH, and that it sets a bad
precedent to solve the problems of the NIH through state funding).
179. The Stem-Cell State, 432 NATURE 131, 131 (Nov. 11, 2004) (noting that there is
still a chance that President George Bush and his allies in Congress who oppose the research
could undermine Proposition 71 with a federal ban in essential techniques such as
'therapeutic cloning,' but that such a bill has failed twice in the Senate already).
180. Id. (indicating that researchers outside California worry that Proposition 71 could
weaken embryonic stem cell research elsewhere because while privately-funded research
centers exist outside California, even senior researchers may find it difficult to pass up
funding and lab space).
181. Jonathan Knight, Joys Match Fears as California Agrees to Stem Cell Proposal,
432 NATURE 135, 135 (Nov. 11, 2004) ("In response to such pressures, other states may
consider stem-cell measures of their own, suggests Kevin Wilson, a spokesman for the
American Society for Cell Biology.. . 'There could be a domino effect,' he predicts.").
182. William Safire, Op-Ed., California's Stem Cell Gold Rush, N.Y. TIMES, Dec. 15,
2004, at A33 (giving examples of federalism in action).
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this research at the state level. Researchers wishing to engage in frontier
science have limited choices. They can either attempt to solicit private
funding at the institute where they currently research or move to a state with
a commitment to funding the research.
V. IMPLICATIONS OF STATE COMPETITION AND/OR FEDERAL
INTERVENTION
A wide breadth of literature in corporate law concerns the relationship
between state competition and federalism. Legal scholarship focuses on
whether competition among states to attract corporations results in a "race-
to-the-bottom" or "race-to-the-top."' 183 More recent scholarship argues that
state competition to attract corporations does not exist due to Delaware's
dominant position in the market for incorporation. 84 However, Delaware's
fear of federal regulation affects its policy.1
8 5
Will the recent California stem cell legislation cause a similar effect by
attracting leading scientists, biotech and pharmaceutical companies to move
to California and leave other states? Due to its favorable legal
infrastructure and biomedical policy contributing to "agglomeration
economies,"' 186 California may be so far in the lead that other states may
only be able to conduct research on a much smaller scale.'87 Put in another
way, Proposition 71 may attract leading scientists to a state that already has
favorable conditions for start-up biotech companies. Other states, such as
New Jersey and Massachusetts, may continue to draft, pass, and fund pro-
stem cell research policy in an attempt to emulate California so as to also
profit from scientific innovation. However, these states may not be able to
provide the same advantageous resources that already exist in California,
thereby making it difficult to catch up.
The federal government, perhaps California's most formidable opponent,
may act to provide pro- or anti-stem cell policies or may choose to allow a
state-regulated model to persist. A potential disadvantage under the state-
regulated model is that scientists in different states cannot collaborate with
one another if the state policies differ. Under a pro-stem cell federal policy,
183. Robert Romano, The State Competition Debate in Corporate Law, 8 CARDOZO. L.
REV. 709, 711 (1987).
184. Lucian Arye Bebchuk & Assaf Hamdani, I igorous Race or Leisurelv Walk:
Reconsidering the Competition over Corporate Charters, 112 YALE L.J. 553, 556 (2002).
185. Mark J. Roe, Delaware's Competition, 117 HARV. L. REv. 588, 591-2 (2003).
186. Ronald J. Gilson, The Legal Infrastructure of High Technologv Industrial Districts:
Silicon Valley, Route 128, and Covenants Not to Compete, 74 N.Y.U. L. REV. 575, 576 (
1999) (discussing Alfred Marshall's writing that described industrial districts and his
development of the concept of "agglomeration economies").
187. Id. at 576.
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all scientists will have the opportunity to work with one another. In
addition, the federal government should enact policies to oversee
responsible stem cell research before the states or researchers in the private
sector conduct ethically questionable experiments. Moreover, the amount
of federal dollars that can be appropriated to stem cell research far surpasses
what individual states can afford and scientific progress will move faster if
laboratories around the country all receive federal funding.188 On the other
hand, although the federal government has not passed anti-stem cell
legislation, California's policy may cause a federal backlash. This state
behavior may give anti-stem cell federal legislators the ammunition needed
to convince borderline votes to pass legislation that preempts state law with
a federal ban, which could halt stem cell research in this country for years
to come.
A. State Competition Under Corporate Law
State policymakers are aware that different legal infrastructures can
attract industry. Delaware currently provides the most attractive corporate
laws for large corporations in the country.'8 9 Underscoring the state-
competition model for corporate law, some scholars argue that state laws
lead to a race-to-the-bottom, where protections of management interests
outweigh shareholder protections.'"9 Others argue that state competition
leads to a race-to-the-top, where state laws protect shareholders' interests
because investors can sell their shares if managers do not perform
optimally. 19' Similar to corporate law, state policy that offers incentives to
researchers and industry interested in stem cells will move scientists to
states offering those opportunities. California not only currently offers the
most freedom and resources to conduct stem cell research, the state's
businesses also stand to make a tremendous amount of money if stem cell
research leads to the effective treatment of a variety of diseases. 
92
188. See Bruck, supra note 12, at 64 (noting that the NIH's budget in 2003 was $27.3
Billion, $190.7 million of which was allocated to adult stem cell research and $24.8 million
to embryonic stem cell research).
189. Bebchuk & Hamdani, supra note 184, at 554.
190. William L. Cary, Federalism and Corporate Law: Reflections Upon Delaware, 83
YALE L.J. 663, 666 (1974) (explaining the competition for corporations leads to a "race to
the bottom" because states have "watered [down] the rights of shareholders vis-A-vis
management.").
191. Romano, supra note 183, at 711 (discussing the state competition literature, citing
Winter, State Law, Shareholder Protection, and the Theory of the Corporation, 6 J. Legal
Stud. 251, 255 (1977)).
192. Broder & Pollack, supra note 32, at Al (noting that a study, financed by the
initiative's proponents, predicted that research would generate between $537 million and
$1.1 billion in royalties to the state over the next 35 years).
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1. The Potential Effects of Proposition 71 Do Not Follow the Race-to-the-
Top or Race-to-the-Bottom State Competition M idels
William Cary defines the race-to-the-bottom as a system where the legal
infrastructure, enforced by the courts, allows an environment in which
corporate management is able to benefit most from their decisions without
regard to the needs of the shareholder. An important aspect of Cary's
argument for the race-to-the-bottom theory is the composition of the
Delaware bench and the "relationship between politics, the bar, and the
judiciary."1 3  Cary connected seven justices of the Supreme Court of
Delaware from 1951 to 1974 to the drafting of Delaware corporate law.
194
Indeed, Delaware's Court of Chancery specializes in corporate law and
publishes its opinions, thereby creating a body of corporate case law,
meaning many corporations prefer to litigate in Delaware due to the case
law history. 1
95
To analogize Proposition 71 to Cary's race-to-the-bottom model, the
shareholders are the citizens of California and management is represented
by the proposition proponents and those who control the $3 billion of
research money. A group called Doctors, Patients and Taxpayers for Fiscal
Responsibility opposed Proposition 71, claiming that the people who stand
to benefit the most are the venture capitalists and biotech companies who
pushed the initiative forward.1
9 6
Recently, Governor Schwarzenegger appointed Robert Klein as the new
chairman of the Citizen's Committee to oversee the newly formed Research
Institute for Regenerative Medicine. 197 Some critics of this appointment
suggest that a more thorough candidate search should have been
193. Cary, supra note 190, at 692.
194. Id. at 690-91 ("What is striking about the membership of the court in the last 23
years is that almost all the justices were drawn from the group responsible for the 1967
revision of the corporation law.").
195. Id See also Marcel Kahan & Ehud Kamar, The M',th of State Competition in
Corporate Law, 55 STAN. L. REv. 679, 708 (2002) ("A principal attraction of incorporating
in Delaware is the high quality of its chancery court... and the opinions of the court are
published in the state and regional reporter, and are available on commercial databases,
creating a body of case law that provides guidance to practitioners.").
196. Knight - War, supra note 166, at 125 ("The true winners... are the initiative's
sponsors. Most of the S2.6 million so far raised to support the ballot drive has come from
venture capitalists and biotechnology entrepreneurs who stand to gain from its passage.").
197. Carolyn Marshall, Financier To Lead Institute On Stem Cells, N.Y. TIMEs, Dec. 18,
2004, at A13 ("The real estate developer who helped write and finance a ballot initiative to
create a California stem cell institute was elected on Friday to a six-year term as chairman of
the committee that oversees it."); Safire, supra note 182, at A33 ("As the driving force
behind the initiative to invest $3 billion in stem cell research over the next decade, the
builder-financier [Robert Klein II] has just been nominated by Gov. Arnold Schwarzenegger
to head the citizens' committee overseeing the state's Institute for Regenerative Medicine.").
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performed.1 " It is unclear at this time whether those venture capitalists and
biotech investors responsible for funding may be the same people receiving
the grant money and profiting publicly and personally from Proposition 71,
with some arguing that Proposition 71 is a form of corporate welfare.' 99
Unlike Cary's corporate law model, however, Proposition 71 will most
likely not follow a state competition model that may lead to a race-to-the-
bottom. First, if research funded by Proposition 71 does not produce
clinical results in the next ten years, it seems unlikely that the voters of
California will pass initiatives for additional funding. Second, biotech
companies must consider their own shareholders and investors. Those
companies receiving Proposition 71 funding will need to conduct
innovative and successful research in order to obtain additional funding,
retain their current shareholders, and attract new investors. The incentive to
"earn" additional funding through successful research will translate to
benefits for the shareholders, so that the profit-seeking motive will balance
the interests between the managers and the shareholders. Thus, a second
tier of manager-shareholder relations will control the potential for a race-to-
the-bottom that could potentially harm the citizens of California.
Third, academic scientists will most likely operate under Proposition 71
as they do under NIH funding by writing competitive grant applications,
receiving funding, and then applying the grant money to support research in
their laboratories. While university professors do not answer to
"shareholders," the potential of additional funding motivates them to
produce and publish quality research. Such an incentive will most likely
encourage them to use Proposition 71 funding in the most scientifically
optimal manner, without financial motivations that would hurt California's
citizens. Thus, the incentives to perform stem cell research in California, or
any other state, would not create a race-to-the-bottom.
In opposition to Cary's race-to-the-bottom theory, Ralph Winter argued
that if management chose to incorporate (or reincorporate) in a state with
interests adverse to the shareholder, then the "investors would require a
higher return on capital to finance the business operating under the inferior
legal regime., '200 In contrast, under a value-maximizing regime, biotech
firms and industry would strike a balance between the hunger of
management to dive into the lucrative pool of stem cell research with the
interests and investments of the stockholders. While Winter's corporate
model may be applied to the management-shareholder relationship in
198. Marshall, supra note 197, at A13 (describing how some criticize the appointment
of Robert Klein as chairman of the Independent Citizens Oversight Committee).
199. Bruck, supra note 12, at 77.
200. Romano, supra note 183, at 711 (summarizing Winter's argument in response to
Cary).
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biotech companies as discussed above, most likely this relationship will not
be the incentive for biomedical industries to re-locate to California. More
likely, as discussed in more detail below, the pro-stem cell research policy,
combined with the established scientific clusters such as Silicon Valley,
will make it very difficult, if not impossible, for other states to compete
with California.
2. Proposition 71 May Increase the Agglomeration of Biotech Industry in
California
Once Proposition 71 passed, New Jersey immediately announced its
intention to increase funding for stem cell research. The fear that industries
may leave their home state to move to a state that permits stem cell research
is very real. Thus, states may attempt to compete to retain and attract
industry by using state revenue.
In an analogous system, Ronald Gilson argues that the differences in
legal infrastructure in California and Massachusetts explain, in part, the
reason for the success of California's Silicon Valley and the decline of
Boston's Route 128.201 Building on Alfred Marshall's concept of
"agglomeration economies," Gilson argues that Silicon Valley benefits
from the lack of enforcement of covenants not to compete in California,
thereby leading to employee mobility and more dynamic diffusion of
knowledge of the industry.0 2 In response to employee mobility, Silicon
Valley employers realized that in order to succeed they should adopt a
strategy of cooperation and competition that leads to collaboration between
universities and biotech companies, both large and small.20 3 On the other
hand, because post-employment covenants not to compete seem to be
regularly enforced in Massachusetts, employees in the high technology
industries lack mobility, and thus corporations are encouraged to function
on the less successful corporate and scientific model of vertical integration
and internal innovation. 204  Taken together, Gilson argues that the
differences in legal infrastructure and subsequent externalities led to the
201. Gilson, supra note 186, at 577.
202. Id. at 576-78. (discussing how legal infrastructure impacts the dynamics of
industrial districts, particularly those in high technology).
203. Id. at 608-09 ("Employees learned that they could leave; employers learned that
they could not prevent high velocity employment and the resulting knowledge spillover.
And that legal infrastructure caused employers, however reluctantly, to adopt a different
strategy, one of cooperation and competition, that generated a dynamic process leading to
Silicon Valley's characteristic employee career pattern .... ").
204. Id. at 606 (discussing how Silicon Valley's legal infrastructure yielded conditions
able to support "a second-stage agglomeration economy," allowing it thrive while Route
128's infrastructure led to its decline).
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success and decline of two similar industries situated in different states.
Proposition 71 gives California another advantage to attract and retain
scientists and industry to its already expanding and successful biomedical
industry. The collaborative biotech environment already established by the
legal infrastructure as discussed above is fertile ground for an explosion of
stem cell research now that the state is offering a large amount of research
money. Indeed, California may already be so far ahead of other states that
no other states, including New Jersey, will be able to compete. Thus, the
"agglomerization economies" theory more aptly explains why California's
position does not fit under a state "race" model as described above.
Many scholars, as noted below, suggest that Delaware no longer fits
under a state-competition model, but is kept "in check" by fear of federal
pre-emption. 0 - In general, the federal government does not intervene to
regulate corporate law unless it feels that the states are not protecting their
• • 06
citizens. Passage of the Sarbanes-Oxley Act is a recent example of such
federal intervention. 0 7 The situation with California is slightly different,
because normally the federal government is the principle leader of
biomedical policy and funding.20  California, unhappy with the lack of
federal funding for stem cell research, took its own initiative to implement
policy and funding. But this type of state action could cause the federal
government to pass stem cell legislation. If Congress decides to pass stem
cell legislation, it could either support stem cell research or preemptively
ban it and all state law, which would make the federal government the most
formidable opponent to California's efforts.
B. Federal Involvement to Control Slate Behavior
Perhaps the larger issue with the states legislating stem cell research is
the invitation for the federal government to take stronger steps to pre-empt
state behavior.
For the majority of publicly funded biomedical research, the NIH
undergoes public comment on its policy, sets a national standard, and
institutes a peer-review process for grant review. 20 9 Traditionally, the NIH
205. Bebchuk & Hamdami, supra note 184, at 604-05.
206. See id
207. Sarbanes-Oxley Act of 2002, Pub. L. No. 107-204, 116 Stat. 745 (codified in
scattered sections of 11, 15, 18, 28, and 29 U.S.C.). See also Mark J. Roe, Delaware's
Competition, 117 HARV. L. REv. 588, 632-35 (2003) (discussing components of the
Sarbanes-Oxley Act).
208. See Bruck, supra note 12, at 64 (explaining that traditionally decisions about
federal funding have been made by the NIH, the "world's leading medical-research
institution, which awards more than forty thousand research grants each year.").
209. Nat'l Inst. of Health, About NIH, http://www.nih.gov/about/researchplanning.htm
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funds research grants regardless of the laboratory's domicile. While private
persons and organizations may donate money to fund research, the vast
majority of basic science research stems from federal money.1 Moreover,
state funding will not be able to reach the amount of money the federal
government can invest into research. 2 ' The NIH has tackled other difficult
research issues, including recombinant DNA technology. 21 2 However, stem
cell research marks the first time that states have taken action to move
forward with research that the federal government does not support. Here,
California again may find that its strongest opponent is the federal
government.
The federal government may decide to pass legislation on issues not
addressed by state law or it may find a state law so egregious that it
responds by passing federal legislation to pre-empt state law.21 3 For
example, some scholars argue that Delaware's corporate law is not
encouraged by state competition, but rather is kept in check by the fear of
federal action.' 4  While the federal government has not stepped in to
mandate a national incorporation policy, it certainly enters the corporate
realm on specific issues, most notably secunities. 2 " Recent examples
include the Enron and WorldCom corporate scandals, which led to the
passage of the Sarbanes-Oxley Act, setting standards for such issues as
managerial duties and the chain of command for authority within a
corporation.21 6
It may be irrelevant whether California will spawn state competition for
researchers and industries if the federal government intervenes to displace
the state policy. At the two extremes, the federal government could either
change the current stem cell policy to reflect that of the Clinton era, seeking
to establish policy, guidelines, and grants to fund stem cell research, or it
(last visited Oct. 30, 2005).
210. Bruck, supra note 12, at 64; Nicholas Wade, Bush Policy on Human Stem Cells
Faces ne" Challenges, N.Y. TIMES, Mar. 4, 2004, at A 18.
211. See Bruck, supra note 12, at 64.
212. Id. at 67 (explaining that risks of allowing recombnant-DNA research seemed
"frightening" before breakthroughs and benefits came about).
213. Roe, supra note 185, at 601. (commenting that the federal government replaces and
modifies state legislation it finds offensive).
214. Id. at 591-92 (arguing that even if corporate matters remain at the discretion of
Delaware, the federal government has frequently taken away the state's power to create
corporate law); Bebchuk & Hamdani, supra note 184 (commenting that Delaware is so
dominant in corporate law that other states are not a challenge to its position); Kahan &
Kamar, supra note 195, at 685 (arguing state competition may have existed in the past and
may exist in the future, but it does not exist right now).
215. Roe, supra note 185, at 592.
216. Id. at 598 (discussing how Sarbanes-Oxley demonstrates Congress's willingness to
pre-empt state corporate law).
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could pass legislation banning all stem cell research and thereby pre-empt
state policy.
1. The Federal Government Should Regulate and Fund Stem Cell
Research
In 1998, the Clinton administration established that federal funds, via the
NIH, could support research involving embryonic stem cells. This decision
was not the first time the federal government took steps to advance
controversial research through the NIH. An earlier example is the
promotion of recombinant DNA technology.2 17 Initially, critics believed
that synthesizing DNA could be used to create microbes that were
dangerous to the public.21 8 However, a strict set of guidelines developed to
shape recombinant DNA technology and this area of research provided
many medical benefits, including the production of insulin. 1 9
Establishing national guidelines for progress in stem cell research can
address most ethical controversies and ensure research is conducted
responsibly. Without federal policy, an ethical investigation, similar to one
conducted in South Korea, may be required in the United States. 2  In
February 2004, a group of Korean scientists published the results of a study
where they obtained stem cells from a cloned human embryo using
SCNT.221 The study was a first step towards the idea that a patient's own
cells may be used for treatment, thus avoiding an immune response.
However, ethical issues soon came to light concerning how the South
Korean research team obtained the eggs used in the experiments. 222 It is
unclear whether a Ph.D. candidate in the Korean lab donated her own eggs
for the research.223  If true, some argue that women researchers will be
pressured to donate their own eggs when, for the best interests of all
involved, the donor and research should be at arms-length.224
217. Bruck, supra note 12, at 67.
218. Id.
219. Id. (discussing Paul Berg's instrumental work in the 1970s promoting NIH
guidelines for recombinant DNA technology).
220. David Cyranski, Korea's Stem-Cell Stars Dogged by Suspicion of Ethical Breach,
429 NATURE 3 (May 6, 2004).
221. Hwang, W.S. et al, Evidence of a Pluripotent Human Embryonic Stem Cell Line
Derived From a Cloned Blastocyst, 303 SCIENCE 1669, 1669-74 (Mar. 12, 2004); David
Cyranski, Crunch Time for Korea's Cloners, 429 NATURE 12, 13-14 (May 6, 2004)
(describing the work of the Korean scientists) [hereinafter Crunch Time].
222. Crunch Time, supra note 221, at 13.
223. Id. (describing how a Ph.D. student in the lab initially said she donated her eggs
and then later retracted the statement).
224. Id. (discussing how bioethicists are concerned that not maintaining such a boundary
could give rise to researchers directly influencing donors).
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One of the biggest concerns with the South Korean study was that the lab
performed experiments without the government's legal or ethical
oversight.225 The Korean researchers argue they received approval by an
institutional review board, but in a letter to Science in August 2004, the
president of the Korean Bioethics Association, Sang-Yong Song, stated,
"We believe that is premature to perform this research before these issues
had been resolved ... [and] [t]he Korean government is working to prepare
regulations, guidelines, and review systems for biotechnology research in
,226 1diptkeeping with global standards." A similar dispute could easily arise in
the United States without national guidelines in place.
The individual states and the private sector and are not technically
governed by national ethical guidelines with respect to obtaining the stem
cell material and the limitations on how research is conducted. However,
organizations concerned with ethical and responsible stem cell research
have issued proposed guidelines for use by privately-funded researchers,227
which could be used as persuasive evidence of accepted practice in any
suits challenging researcher behavior. In addition, proponents of stem cell
research arguably have incentives to conduct ethically responsible research
so as not to antagonize the federal government to enact further anti-stem
cell policy.
With individual states also enacting their own guidelines, research may
be limited by interstate differences because a scientist in one state may be
unable to collaborate with scientists in other states. For example, if State A
allows scientists to work with newly established stem cell lines, while State
B does not, joint research will be impaired. A national policy allowing stem
cell research would alleviate this problem by providing guidelines that
allow scientists in all states to collaborate with one another, as well
potentially with international scientists. Increased interaction and
collaboration would better promote the great potential for stem cell research
to help patients.
State initiatives to promote stem cell research are laudable. However,
unlocking the full potential of this research will require the type of long-
term, broad financial support only the federal government can sustain.
Research will progress more quickly and more people will potentially be
helped if the NIH adopts the Clinton administration's pro-stem cell research
policy. The United States federal government should follow the lead of
225. Sang-Yong Song, Stem Cell Research in Korea, 305 SCIENCE 944, 944 (Aug. 13,
2004).
226. Id. at 945.
227. See, e.g., Cmte. on Guidelines for Human Embryonic Stem Cell Research, Nat'l
Research Council, Guidelines for Human Embryonic Stem Cell Research: Executive
Summary, available at: http://www.nap.edu/execsummpdf/1 1278.pdf.
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Great Britain by implementing ethical and safety guidelines and funding the
promotion of stem cell research.
Sound guidelines for supporting stem cell research include requiring
non-compensatory consent for donation of fertilized eggs, limiting the time
the blastocysts can be grown in a petri dish, and establishing a federal stem
cell bank. In addition, the NIH offers a preexisting functional infrastructure
to enact guidelines, fund peer-reviewed research grants, and establish a
stem cell bank depository such that scientists among the states can
collaborate with each other and also work with other scientists around the
world. In this way, the United States will establish uniformity throughout
the country when conducting stem cell research.
2. State Policy Promoting Stem Cell Research Could Potentially Cause
Federal Retaliation and Halt Stem Cell Research
On August 9, 2001, President Bush announced his stem cell research
policy that only stem cell lines created before that date could be used for
federally-funded research and that no new stem cell lines could be created
using federal funds .228 The House of Representatives passed a bill that
criminalizes both therapeutic and reproductive cloning with punishment of
a fine of at least $1 million and up to ten years in prison.229 This bill,
however, does not have the votes to pass the Senate.23° Senator Orrin Hatch
(R-UT) sponsored a bill in the Senate that would prohibit reproductive
cloning but allow therapeutic cloning.231 This bill has not passed the Senate
and President Bush says he would veto such a bill. 232  To date, the
government does not have federal law with respect to reproductive or
therapeutic cloning technology.
If the anti-stem cell politicians in Washington gain momentum to
legislatively ban stem cell research, one of the only things that can save pro-
stem cell policy is a therapeutic breakthrough. If the public sees the
promise of research to patients able to receive effective treatment using
stem cell technology, then President Bush and other similarly-aligned
politicians will have a hard time taking those treatments away from the
American public. Research is an expensive, slow, and laborious process,
228. NIH's Role in Federal Policy, supra note 18.
229. Brainard, supra note 19 (describing the House Bill to ban cloning); Grady, supra
note 19, at B12.
230. Brainard, supra note 19, at A24 (explaining the Senate has the votes to stop the bill
from passing); Grady, supra note 19, at B12 (discussing the two bills in the Senate).
231. Human Cloning Ban and Stem Cell Research Protection Act of 2003, S. 303, 108th
Cong. (2003) (bill prohibiting reproductive cloning but allows for stem cell research).
232. Brainard, supra note 19, at A24 (discussing that President Bush promised to veto
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and the real "race" may be between individual states and the federal
government.
VI. CONCLUSION
This article presents the current state of affairs for stem cell research by
providing an overview of the research, explaining the ethical objections,
describing the federal policy, and illustrating the state and private responses
to the federal restrictions. In recognition of the practical federal ban on
stem cell research, private investors and states took initiative to promote the
scientific, medical, and economic potential of stem cell research. This
dissent against federal policy may lead to state competition for researchers
and industry, but more likely, it will induce a federal reaction. It is unclear
at this time whether the federal government will enact policy to support the
ethical promotion of therapeutic research or ban stem cell research, thus
stifling progress in this country for years to come.
